Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanostart to feature successful completion of MagForce clinical trials at investor presentation in New York City

Abstract:
* Exclusive event for 80 specially invited guests
* Highlight: Clinical efficacy of Nano-Cancer®-therapy now proven
* Growing investor interest in Nanostart and its protfolio companies

Nanostart to feature successful completion of MagForce clinical trials at investor presentation in New York City

Frankfurt | Posted on November 4th, 2009

Marco Beckmann, CEO of Nanostart AG, the global nanotechnology investment company based in Frankfurt, will be presenting the company and its portfolio holdings to an audience of approx. 80 selected investors and analysts on November 5 in New York City's Manhattan Club.

The occasion for this special investor event is first and foremost the superb results of clinical trials reported by MagForce Nanotechnologies AG (ISIN DE000A0HGQF5), which is 77% owned by Nanostart. On November 3, MagForce announced the successful completion of its clinical trials demonstrating the efficacy of its Nano-Cancer® therapy in treating recurrent glioblastoma, a particularly malignant form of brain tumor. The median survival time was more than doubled in the patient group, far in excess of the study objective. These clinical trials thus conclusively demonstrated the efficacy of Nano-Cancer® therapy. The study also confirmed that the therapy is extremely well tolerated by patients compared to conventional therapies, with no significant side effects.

The presentation will take place as part of an evening program. Marco Beckman will be in the spotlight as the event's sole speaker, and guests will have ample time following the formal presentation to speak individually with him and to ask detailed questions.

Vanessa Mieschke, responsible for investor relations at Nanostart, commented: "With these superb results from its clinical trials, our majority-owned MagForce is entering into a new era. Large U.S. investors have been awaiting these results with anxious anticipation."

Disclaimer: This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

####

About Nanostart
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector.

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122

Copyright © Nanostart

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014

New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014

Chemical interactions between silver nanoparticles and thiols: A comparison of mercaptohexanol again September 30th, 2014

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

Investments/IPO's/Splits

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Nanomedicine

Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014

New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

How things coil: Researchers discover that simulation technology designed for Hollywood can be used as a predictive tool for understanding fundamental engineering problems September 29th, 2014

Announcements

Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014

New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014

Chemical interactions between silver nanoparticles and thiols: A comparison of mercaptohexanol again September 30th, 2014

A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014

Events/Classes

Oxford Instruments launches 3rd annual Indian nanotechnology seminars in Kolkata and Delhi - sharing expertise with Nanotechnology researchers in India September 25th, 2014

Grenoble Hosting SEMICON Europa Oct. 7-9, First Time Event Held in France: Leti’s 90-square-meter Booth Will Feature Portable Showroom To Demonstrate New Technology Innovations September 24th, 2014

Contributing to the spirit of the IYCR 2014 September 24th, 2014

BSA Distinguished Lecture Tuesday, 10/14: 'LCLS: A Stunning New View Through X-ray Laser Eyes' September 23rd, 2014

Nanobiotechnology

Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014

How things coil: Researchers discover that simulation technology designed for Hollywood can be used as a predictive tool for understanding fundamental engineering problems September 29th, 2014

Penn Team Studies Nanocrystals by Passing Them Through Tiny Pores September 26th, 2014

New NIH/DOE Grant for Life Science Studies at NSLS-II: Funding will support operation of three powerful experimental stations designed to reveal detailed structures of proteins, viruses, and more September 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE